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We review here the status of human type 2 diabetes studies from a genetic, epidemiologi-
cal, and clinical (intervention) perspective. Most studies limit analyses to one or a few omic
technologies providing data of components of physiological processes. Since all chronic
diseases are multifactorial and arise from complex interactions between genetic makeup
and environment, type 2 diabetes mellitus (T2DM) is a collection of sub-phenotypes
resulting in high fasting glucose. The underlying gene–environment interactions that
produce these classes of T2DM are imperfectly characterized. Based on assessments
of the complexity of T2DM, we propose a systems biology approach to advance the
understanding of origin, onset, development, prevention, and treatment of this complex
disease. This systems-based strategy is based on new study design principles and the
integrated application of omics technologies: we pursue longitudinal studies in which each
subject is analyzed at both homeostasis and after (healthy and safe) challenges. Each
enrolled subject functions thereby as their own case and control and this design avoids
assigning the subjects a priori to case and control groups based on limited phenotyping.
Analyses at different time points along this longitudinal investigation are performed with
a comprehensive set of omics platforms. These data sets are generated in a biological
context, rather than biochemical compound class-driven manner, which we term “systems
omics.”
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INTRODUCTION
Type 2 diabetes mellitus (T2DM) is a complex disease with
epidemic proportions. The International Diabetes Federation esti-
mates a total of 371 million type 2 diabetics worldwide1. China
and India alone account for more than 150 million cases. Hence,
there is a public health, economic, scientiﬁc, and ethical call
for a proactive and preventive approach to the individual and
public health burden caused by diabetes and its co-morbidities.
Scientiﬁcally based preventive approaches should complement
the reactive, pharmaceutical approach of management and treat-
ment.
Type 2 diabetes mellitus is a multi-factorial condition that can
already occur during gestation and has variable onset, severity, and
outcome in juveniles, adults, and the elderly. Genetic (predisposi-
tion), epigenetic (developmental programing), and environmental
factors (diet and physical activity) contribute to T2DM, with
epigenetic contributors so far only being suggested from an epi-
demiological and animal model perspective. The complexity of
the T2DM phenotype has challenged the fragmented scientiﬁc
approaches, typically focusing on either genetic, or environmental
(diet, lifestyle), or socio-economic conditions in isolation rather
Abbreviations: LC, liquid chromatography; MODY, maturity onset diabetes in the
young; MS, mass spectrometry; T2DM, type 2 diabetes mellitus.
1http://www.idf.org/diabetesatlas/5e/Update2012
than on multi-scale, longitudinal, systems-level studies, which we
explain here.
Although systems biology is considered an emerging paradigm
for biological research, its roots can be traced back to
von Bertalanffy (1951). Systems research typically refers to inte-
grating combinations of high-dimensional (epi)genomic, tran-
scriptomic, proteomic, or metabonomic data. Conceptual experi-
mental approaches have been proposed for obesity, diabetes, and
cardiovascular disease (MacLellan et al., 2012; Zhao et al., 2012;
Meng et al., 2013). However, only a few multi-scale experimental
results have been reported (Morine et al., 2010, 2011; Lau et al.,
2012). Many of these examples analyze the physiological system
– that is, the system is deﬁned as processes occurring within the
body. However, environmental factors such as nutrition, activity,
rest/sleep, exposures to toxins and stress, and psychological factors,
are known to inﬂuence an organism’s physiology, too.
Our deﬁnition of a “multi-scale systems” approach means deep
characterization of subjects at omic and clinical level, and –
importantly – as many environmental factors as possible, and inte-
gration of these data (Figure 1) in interaction networks (including
both functional interactions and statistical correlations). “Lon-
gitudinal” means that every study subject is assessed multiple
times and ideally with challenges to homeostasis (van Ommen
et al., 2009). These combined approaches differ from the standard
methodology, in which single homeostatic “snapshots” are taken
www.frontiersin.org October 2013 | Volume 4 | Article 205 | 1
“fgene-04-00205” — 2013/10/14 — 12:08 — page 2 — #2
Kussmann et al. Systems approach to diabetes research
FIGURE 1 | Systems approach to analyses of complex traits. Systems
research typically focuses on data measured (objects with dashed lines) from
accessible tissues (adipose, muscle, occasionally other biopsies) and body
ﬂuids. Hence, many systems studies are analyzing a small subset of, e.g., the
total metabolite complement. Since the measured molecules (proteins,
RNAs, metabolites, etc.) are inﬂuenced by the expression of genomic
information, DNA must also be characterized: the level and relationships
between biomarkers are context-speciﬁc and the context here is the genes
inherited from parents. DNA methylation, microRNAs, and chromatin
modifying enzymes also change the expression of genetic information and
can be measured in some tissues. These regulators are in turn regulated by
environmental signals of nutrients and bioactives in food, and by a large
number of physiological factors (sleep, ability to handle stress, joy) and
personal (activity) and public environmental conditions (pollutants, allergens,
alleochemicals from food, etc.). Many of these factors are not measured in
systems research but they directly or indirectly can inﬂuence expression of
genetic information. These metadata need to be captured in future
experiments to understand the context of the physiological measurements
and outcomes. The challenge of systems research is integrating these
multi-scale data sets, which is still in its infancy.
between a priori deﬁned groups of subjects, which are assumed to
be matched for age, gender, genetic, socio-economic, or other con-
founders. These studies are furthermore often technology-driven,
assuming that improvements in high-throughput genomics, tran-
scriptomics, proteomics, or metabonomics sufﬁce to correlate
molecular signatures with disease phenotype. This goal has, how-
ever, been difﬁcult to achieve, particularly in complex diseases,
due in part to molecular and clinical heterogeneity between
“cases.”
Wedonot conduct our human clinical studies by assigning sub-
jects to groups based on a limited number of parameters. Rather,
we propose a longitudinal study design, in which the same study
subject is repeatedly monitored over time and individuals with like
response are assigned tometabolic response groups only aftermul-
tidimensional characterization. This approach uses each subject
as their own control, challenging the classical case–control study
design. Such an individual-focused longitudinal approach centers
on analysis of trajectories of each measured variable over time.
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Moreover, instead of studying a phenotype at homeostasis only,
we expose subjects to metabolic challenges (e.g., oral glucose toler-
ance, high-fat meals or diets, physical exercise, or cognitive tests)
and probe their metabolic elasticity, i.e., how rapidly or slowly
they return to homeostasis after such safe, acute challenges. These
repeated challenges and their omic read-outs of the body’s reac-
tions can enable better deﬁnition of an individual’s health status
and, potentially, their susceptibility to disease. A case in point:
women who develop gestational diabetes during the stress of preg-
nancy are at a ﬁve-fold greater risk for developing T2DM; hence,
metabolic responses to homeostatic challenges in healthy subjects
may identify susceptibilities to later disease, which would derail
their healthy trajectory before symptoms occur. These insights can
in turn reveal early biomarkers for emergingmetabolic disease and
signatures for metabolic groups.
The integration of the comprehensive analyses of an individ-
ual’s genetic predisposition, epigenetic programing, and reaction
at all omic levels may pose problems of too high dimensionality.
However, we take a systems approach rather than a biochemi-
cal compound-class approach in the sense of completely mapping
out key pathways and networks in diabetes (i.e., identifying and
quantifying all enzymes, nutrients, and metabolites in those path-
ways). We term this “systems omics” as opposed to “classical”
proteomics/metabonomics/lipidomics.
HUMAN (EPI)GENETIC INDIVIDUALITY WITH REGARD TO
T2DM
Many genetics-oriented studies of diabetes have not taken into
account any information on an individual’s environment, such
as nutrition, physical activity, or lifestyle: typically, genome-wide
association studies (GWAS) in cohorts derived from diabetic and
healthy populations have identiﬁed multiple genetic, population-
attributable (fraction) risk loci. These markers are usually single-
nucleotide polymorphisms (SNPs), which – in combination –
were expected to predict disease risk in individuals. However, they
explain only a fraction of the disease risk, partly because of themis-
perceived deﬁnition of “population-attributable fraction” (PAF),
which is the decrease in disease incidence if the allele were not
present in that population (Rockhill et al., 1998; Kaput, 2008).
Since GWAS is determined by the average occurrence of a SNP
between cases and controls, the risk allele is actually a PAF and
not the personal or individual risk factor. In fact, family history is
a better predictor of diabetes risk than SNPs identiﬁed by GWAS
(Meigs et al., 2008).
A number of authors have identiﬁed limitations in the GWAS
designs (McCarthy et al., 2008; Goldstein, 2009; Manolio et al.,
2009; Need and Goldstein, 2010):
- Poorly deﬁned phenotypes.
- Indirect scoring of causal SNPs by distant gene markers.
- Challenge to ﬁnd rare alleles.
- Insufﬁcient consideration of gene × gene interactions (epis-
tasis).
- Insufﬁcient consideration of gene × environment interac-
tions.
- Copy number variants.
- Epigenetic factors.
In addition, human populations are not at equilibrium with
exponential population growth occurring only during the last
150 years. The consequence of this rapid expansion is that
more recent and rare variants exist than assumed by the com-
mon variant/common disease model, which is the theoretical
basis of the GWAS experimental designs (Cargill and Daley,
2000; Hirschhorn and Daly, 2005; Iyengar and Elston, 2007; Fu
et al., 2013). Hence, the sample size for a representative propor-
tion of the population roughly equals the effective population
size.
Gene–diet interactions have been analyzed in humans, but
typically in a single-gene versus single-nutrient design, where a
complex phenotype (such as response to nutrient) is thought to
be caused by a single variant in one gene out of a total of ∼20,000
human genes. Although selected gene–diet associations have been
replicated in multiple populations, e.g., in the study “Association
between the APOA2 promoter polymorphism and body weight
in Mediterranean and Asian populations: replication of a gene-
saturated fat interaction” (Corella et al., 2011), the effect size of
these associations is known to explain only a small percentage of
the overall phenotype. Alternatively, classical nutritional epidemi-
ology studies associating anutrient to aphenotypewere performed
in clinical cohorts or in entire (sub)populations, and these studies
neglected the genetic contributions to the phenotype. This design
is based on the assumption of ﬁnding the statistical main effect of
the diet or lifestyle.
It is well established that genetic factors contribute signiﬁcantly
to T2DM. Estimates of heritability for T2D range from 50% to
80% and are much higher than for T1D. However, these estimates
rely on the assumption that environmental exposures are equal
for those that are affected and those that are not. This may not be
true, even when comparing monozygotic to dizygotic twins (Loos
et al., 2001; Ollikainen et al., 2010). Studies of maturity onset dia-
betes of the young (MODY), a highly penetrantmonogenetic form
of type 2 diabetes, have proven that single gene mutations can
lead to T2DM (Johansson et al., 2012; Mitchell, 2012), although
the age of onset, severity, outcome, and age of death demon-
strate the importance of modifying genes. Many SNPs affect gene
expression or protein function more subtly than loss-of-function
mutations. While not explaining most of the estimated heri-
tability, GWAS have provided new insights into the etiology of
T2DM. One striking and unexpected outcome of genetic studies
of both MODY and late onset T2DM is that most genes identiﬁed
so far are involved in insulin secretion. A caveat though is that
over 90% of GWAS were conducted in Europeans and the ﬁnd-
ings cannot be generalized to other populations. Myles et al., for
example, showed that allele frequencies of a subset of 25 GWAS-
identiﬁed risk alleles were not consistent with contributions to
disease incidence in Africans or Asians (Myles et al., 2008). Oth-
ers have shown that different pathways that alter glucose levels
(i.e., insulin sensitivity, gluconeogenesis, insulin secretion) dif-
fer between ancestral groups (Misra and Vikram, 2004). This
is important from a systems perspective, as it suggests that a
given phenotype can arise from distinct perturbations of system
function, and thus puts into question the assumption of many
GWA studies that all cases are identical from a patho-physiological
viewpoint.
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Nevertheless, the fact that so farmost genes identiﬁed byGWAS
are involved in insulin secretion may shed new light on the role of
obesity and insulin resistance in T2DM etiology. Indeed, one may
speculate that T2DM (like type 1) is fundamentally a β-cell disease
and obesity-related insulin resistance is a secondary risk factor,
which may push “at-risk” individuals across the disease threshold.
The knowledge gap is whether genetic variants involved in insulin
secretion independently increase the risk of T2DM in addition to
the physiological effects caused by high body mass index (BMI).
If we want to prevent T2DM, we need to disentangle the causal
variations and environmental factors. To do this we need new
approaches to studying genetic variation that do not rely on a
design, in which type 2 diabetics with different causal variants
are compared to controls, because individuals classiﬁed as T2DM
and control have highly variable phenotypes. The future and the
success of genetic studies of T2DM will not be solved by ever big-
ger association studies, but rather in well-deﬁned studies enrolling
carefully phenotyped subjects, who should be exposed to a (dietary
or other) external challenge to reveal their individual responses.
New sequencing technologies are expected to identify additional
rare variants with somewhat higher effect sizes. In addition to this
revised study design, data acquisition, processing, and interpreta-
tion also need to be revisited: all molecular and clinical data need
to be regarded as a single input into a systems approach to even-
tually unravel those mechanisms that are the most important risk
factors for a given group of individuals. Only then can we design
effective interventions, either nutritional, life-style or drug-based,
to prevent or at least delay the development of this disease.
HUMAN STUDIES ON T2DM – TODAY AND TOMORROW
Many, if not most, human studies have been designed in a case –
control design with the most important consideration being the
power of the experiment to detect the null hypothesis (Bader,2001;
Longmate, 2001; Lee and Whitmore, 2002; Teo, 2008; Visscher
et al., 2008). An unintended consequence has been an increas-
ing misclassiﬁcation: adding subjects to case or control groups
based on simplistic phenotypic characterization. For example,
most population-based studies use fasting plasma glucose levels
or other homeostatic measures associated with T2DM. However,
elevated fasting glucose levels could be produced by decreased
insulin production, increased gluconeogenesis, insulin insensitiv-
ity, or increased glucose uptake in the intestine (Kaput et al., 2007;
Malecki and Skupien, 2008). Individuals differ in these pathways
and may have different genetic variants that contribute to these
glucose abnormalities. Grouping all subtypes of T2D therefore
decreases the signal and increases noise in these case–control anal-
yses. The failure to account for environment–gene interactions
also confounded GWAS analyses.
Two related approaches may improve study designs and
both require more comprehensive phenotyping before analyz-
ing genetic differences. The ﬁrst approach is to compare genetic
makeup of individuals at the extremes of a given phenotype
(Ahituv et al., 2007; Kaput, 2008; Khor and Goh, 2010). This strat-
egy may work for highly differentiated phenotypes, for example,
tall versus short stature (Lettre, 2009) or the subset of metabolic
phenotypes that can be clearly discriminated by homeostatic
measurements. The second approach uses short-term (acute) or
long-term (chronic) challenges to homeostatic systems or, ide-
ally, a combination of them. The oral glucose tolerance test is
used for assessing glucose regulation and a prime example of
such acute challenges. Other nutritional and functional chal-
lenges (e.g., exercise) may also be used for assessing metabolic
robustness (van Ommen et al., 2009). Results from such chal-
lenge studies using extensive omics, similar to the approach
described in this article, have beenpublished (Wopereis et al., 2009;
Heinzmann et al., 2012) and conﬁrm the large intra-individual
variability observed at homeostasis. However, small sample sizes
limited the ability to cluster individuals with similar responses.
O’Sullivan and coworkers, for example, could group individu-
als based on biomarker patterns following long-term vitamin D
supplementation (O’Sullivan et al., 2011).
We propose here to combine acute challenges of homeostasis,
such as oral glucose tolerance, with longitudinal analyses, ide-
ally following deﬁned nutritional or activity interventions which
alter physical condition, such as weight loss or improved cardio-
vascular health. The response to single homeostatic challenges is
inﬂuenced by the current physiology of the individual: to illustrate,
O2 consumption measured at homeostasis or in acute challenges
(e.g., upon a single exercise bout) will likely differ before and after
months of athletic training. So, which time point and physiology
accurately measures an individual’s aerobic capacity robustness?
The study design and execution suggested here, includ-
ing extensive omics at homeostasis and after acute challenges,
measured longitudinally, increases both cost and complexity
of assessing health and disease. The current model of fund-
ing and conducting biomedical research was designed in the
pre-genomic era. The average research grant in the USA was
US$ 482,276 in 2012 and most grants are 3 year awards, with
resources too small to conduct multi-scale scientiﬁc research2.
While smaller scale science funding must be maintained, the
complexity of biological processes requires complex analysis
that can only be done through extensive collaborations in
consortia. Many examples of these consortia now exist: the
Human Genome (Lander et al., 2001), the International HapMap
(InternationalHapMapConsortium,2003), the ENCODE (Birney
et al., 2007), and the 1000Genomes (The 1000 Genomes Project
Consortium) projects (organized in the United States); and many
of the Framework projects in Europe such as NuGO3, Food4Me4.
The paradigm of funding and conducting biomedical research is
changing.
Human studies of systemic, metabolic conditions like T2DM
must not be restricted to the assessment of the human host only:
humans carry ∼100 times more bacterial than human cells in
and on their body, colonizing mucosal surfaces (e.g., gut, oral
cavity, vagina) and the skin (Ursell et al., 2012). The intestinal
microbiota are the most complex of these bacterial communities
(Dimitrov, 2011) and centrally involved in host metabolic (Harris
et al., 2012) and immune health (Hakansson and Molin, 2011).
We therefore proposed in an earlier perspective published in this
journal an “extended nutrigenomics” approach encompassing the
2http://report.nih.gov/fundingfacts/index.cfm
3http://www.nugo.org
4http://www.food4me.org
Frontiers in Genetics | Nutrigenomics October 2013 | Volume 4 | Article 205 | 4
“fgene-04-00205” — 2013/10/14 — 12:08 — page 5 — #5
Kussmann et al. Systems approach to diabetes research
host, microbial and food genomes to better understand gene–
diet interactions in humans (Kussmann and Van Bladeren, 2011).
Today’s insights into host–microbiome relationships derive from
large-scale (earlier 16 sRNA sequencing, nowadays deep sequenc-
ing) studies and mainly reﬂect associations between a microbial
population census on the one hand and a host condition on the
other hand. It has for example been shown that human subjects
with different metabolic conditions (e.g., diabetes, Larsen et al.,
2010 or obesity, Turnbaugh et al., 2006) have different gut micro-
biota. Next steps have recently been taken toward establishing a
more causal (Knaapen et al., 2013) than purely associative rela-
tionship (Cox et al., 2013): the biochemical activities of such gut
microbial populations have been probed by metabonomic means
and so-termed “core” human microbiomes have been character-
ized with metabolic functions generalizable between individuals
(Huse et al., 2012; Li et al., 2013). This may pave the way for tailor-
ing diets to metabolic groups of consumers and patients to induce
or maintain a favorable microbiome (Nicholson et al., 2005; Wu
et al., 2011). Possible causal relationships between gut microbes
and host health need to be considered from both perspectives:
microbes possibly altering health phenotype and host factors pos-
sibly determiningmicrobial composition. Yokota et al. (2012) took
it from the host end asking whether bile acid is a determinant
of the gut microbiota on a high-fat diet and discussing how the
identiﬁcation of host factors determining the gut microbiota can
contribute to understanding the causality between changes in gut
microbiota and disease development.Vrieze et al. (2013) even took
the ultimate step from causality to possible treatment considering
fecal transplantation as a clinical therapy for restoring intestinal
microbial balance in human disease.
OMICS MONITORING OF HUMAN STUDIES ON T2DM –
TODAY AND TOMORROW
Omics studies in nutrition and diabetes have typically been per-
formed in a technology-driven, rather than a technology-rooted
manner. While the advent of high-throughput and comprehen-
sive genomics and other omic platforms have advanced biological
knowledge, the emphasis on single technology-driven nutritional
and biomedical research projects still limits assessing health and
disease conditions and trajectories: there are a number of inves-
tigations that attempt to ﬁnd either genetic (Billings and Florez,
2010), or epigenetic (Pinney and Simmons, 2010), or proteomic
(Rao et al., 2009; Riaz et al., 2010a,b) or metabonomic (Bao et al.,
2009; Huo et al., 2009; Grifﬁn et al., 2011) biomarkers for T2DM.
Our suggestion is that cross-platform approaches are needed to
truly interrogate physiological processes.
While genetic markers can inform on inborn predisposition
and susceptibility, epigenomics can reveal those genetic marks
altered by the environment, particularly diet (Waterland and Jir-
tle, 2003, 2004; Gluckman et al., 2009; Low et al., 2011). Epigenetic
modiﬁcations increasingly appear todeliver themolecular basis for
the intuitive observation that environment shapes phenotype dur-
ing lifespan and even across generations (Morgan and Whitelaw,
2008; Morris, 2009). However, epigenetic marks do not only affect
DNA bases (methylation) but also the “DNA-packaging” proteins
such as histones (Jenuwein and Allis, 2001), other chromosomal
components that regulate transcription, and small RNAs (Bei
et al., 2007; Choudhuri, 2011). Despite recent developments of
proteomics in deciphering the histone code (Trelle and Jensen,
2007; Sidoli et al., 2012) and the epigenetic interplay between
DNA- and histone modiﬁcations, there are few studies that
integrate proteomics and DNA sequencing to generate a more
complete picture of epigenetic marks that affect gene expression
and phenotype after environmental exposure (Fuks et al., 2003;
Johnson et al., 2007).
A body of pure proteomic approaches is emerging that analyzes
energy metabolism-relevant tissues across different conditions
(pancreas, Chen et al., 2007a,b; Kim et al., 2008; muscle, Wang
et al., 2010; Giebelstein et al., 2012; adipose tissue, Ahmed et al.,
2010; Perez-Perez et al., 2012; pancreatic beta cells, Song et al.,
2009; Maris et al., 2011; and mitochondria, Forner et al., 2006;
Chen et al., 2012). These tissues were typically isolated from nor-
mal (control) and diabetic (case) human subjects, mouse strains
or geneticmousemodels. Potential protein/peptide biomarker sig-
natures are being associated by analyzing blood or urine, in order
to facilitate less invasive sampling.
Metabonomic studies in T2DM can be classiﬁed in those based
on (proton) nuclear magnetic resonance (1H-NMR) spectroscopy
(Rezzi et al., 2007; Lindon and Nicholson, 2008; Collino et al.,
2009), and those deploying mass spectrometry (MS; Toyo’oka,
2008; Kertesz et al., 2009; Mishur and Rea, 2012). NMR-enabled
metabonomic proﬁling in the context of diabetes was typically
done on human urine (Kussmann et al., 2006; Faber et al., 2007;
Maher et al., 2009; Zhao et al., 2010). The intrinsic NMR advan-
tages like high-throughput, robustness, and minimal sample
preparation are now being complemented by the higher sensi-
tivity and greater structure elucidation power of MS (Lenz et al.,
2005; Kussmann et al., 2008). However, investigations integrating
metabonomics with proteomics or even genetics or epigenetics
have remained the exceptions (Holmes et al., 2001; Vilasi et al.,
2007; Hardiman, 2011).
Current proteomic discovery platforms typically span a
dynamic range of 104 to 105 whereas the protein concentration
range in human blood plasma is estimated to be 1012 (Lescuyer
et al., 2007; Surinova et al., 2011). Similarly, current metabonomic
workﬂows cover a range of lipophilic and hydrophilic metabo-
lites (Whiley et al., 2012); carbohydrates (Soo and Hui, 2010),
amino acids and ketones (Suhre et al., 2010); and the complex-
ity of lipid biochemistry has resulted in lipidomics as a specialized
new omics discipline (Ejsing et al., 2009; Shevchenko and Simons,
2010). These proteomic and metabonomic studies are typically
designed from a biochemical, compound-class perspective.
Complementary to the aforementioned study designs we pro-
pose here “systems omics,” i.e., to join forces of transcriptomics,
proteomics, metabonomics, and lipidomics to completely map
out – that is identify and quantify all (micro-)nutrients, metabolic
enzymes and their substrates and products – in a given biochemi-
cal pathway. We thereby aim at deeply characterizing the dynamics
of those pathways that have emerged as consistently (de-)regulated
in a speciﬁc health condition and under relevant environmental –
such as dietary – inﬂuences.
The value of a systems approach was recently demonstrated
by Jain et al. (2013), who described the molecular architecture
of T2DM pathophysiology using multi-omics data, combined
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with physical and genetic interaction networks. Their work was
largelymotivated by the observation that, despite the symptomatic
complexity of T2DM (incl. alteration of immune function, oxida-
tive stress, and nutrient metabolism), the majority of GWAS to
date have failed to highlight these processes as genetic deter-
minants of T2DM onset/progression. Starting with publically
available T2DM GWA data, the authors demonstrated that the
only signiﬁcantly enriched pathway with T2DM SNPs was that
of MODY5. By extending these T2DM SNPs to their ﬁrst-degree
neighbors in physical and genetic interaction networks (creating
a “T2DM interactome”), and incorporating gene expression data
from multiple tissues in healthy and diabetic individuals, they
identiﬁed a range of pathways with known relevance to T2DM.
In particular, the TGFβ signaling pathway contained multiple
genes present in the GWA, interactome, and transcriptomic data
sets. Jain et al. (2013) showed that a multi-omics approach can
reveal disease-related processes that may not be evident in a sin-
gle omics data set, and can also aid biological interpretation of
GWA data.
Based on the components identiﬁed in key T2DM-related path-
ways, we propose that MS assays for all nutrients, enzymes, and
metabolites in these contexts be developed and applied. These
assays are based on single- andmultiple reactionmonitoring (SRM
andMRM)of targetmolecules, so calledMS-based enzyme-linked
immunosorbent assays (ELISAs; Maiolica et al., 2012), which use
sequencing of speciﬁc peptides that are unique surrogates for their
parent protein. For measuring metabolites in this “systems omics”
strategy, intact mass-based metabolite identiﬁcation and quan-
tiﬁcation (the latter requiring either isotope-labeled or unlabeled
internal standards that are either chemically identical or highly
similar to the target analytes) is of high interest. Concomitantly,
high-resolution and high-mass accuracy MS have become the
preferred technology platforms for global, quantitative metabo-
lite proﬁling. Targeted SRM and MRM methods that can ﬁlter,
detect, identify, and quantify selected metabolites against complex
biochemical matrices are powerful platforms in clinical metabo-
nomics, particularly in systems omics studies proposed here.
Omics integration is one way to address the spatial and tem-
poral complexity of type 2 diabetes, being a multi-organ disease
with multiple and interrelated contributing dysfunctions, rather
than “just” a beta cell disorder. A systemic, low-grade, chronic
inﬂammation drives metabolic deteriorations in several organs in
T2DM. This raises the question of both meaningful and feasible
sampling of body tissues and ﬂuids and how one could extrapo-
late from intra-cellular networks to a systemicmulti-organ disease.
Repeated sampling of tissue biopsies during a longitudinal study
is not feasible, because key organs for metabolic function like pan-
creas, liver or gut are only accessible by highly invasive means.
We are therefore restricted to the periphery for sampling, i.e.,
blood, urine, and stool. Blood and urine omics have become stan-
dard approaches to assess protein, peptide (Crosley et al., 2009),
lipid (Song et al., 2013), and metabolite (Guy et al., 2008) proﬁles.
These proﬁles becomemoremeaningfulwhen sampled in the same
individual over time and when metabolic/physical challenges are
compared to the resting condition, as we propose here. Moreover,
5www.genome.jp/kegg/pathway/hsa/hsa04950.html
biomolecular blood proﬁles can inform about homeostasis (or
deviation thereof) whereas urine proﬁles can indicate the body’s
measures (e.g., secretion) to achieve or restore this homeostasis.
White and red blood cells have unique, cell-speciﬁc metabolisms
and may inform about metabolic or immune status if analyzed
in conjunction with hematological analysis of cell types (platelets,
eosinophils, other white blood cell types; Crosley et al., 2009).
Stool samples have become the non-invasive choice to access
the gut microbiota (see previous section; Flores et al., 2012a,b).
Hence, only repeated, peripheral, non-invasive sampling over time
and across challenges is both meaningful and feasible to generate
systems-level insights into a multi-organ disease like T2DM in
humans.
RECONSTRUCTING THE SYSTEM OF T2DM WITH NETWORK
ANALYSIS
With exponential reduction in cost of data generation, processing
and managing, it has become more common to measure multiple
types of omics data in a given study. However, translation of these
omics data sets into concrete knowledge of biological systems is
contingent on informative methods for multi-omics analysis. The
simplest approach to analysis of, for instance, a transcriptomic
and proteomic data set, would be to generate lists of genes and
proteins that respond to a given perturbation or correlate with a
given phenotype, then attempt to build a biological interpretation
post hoc. However, this analytical approach does not capture the
functional interactions within and between the different classes of
molecular species, which ultimately coalesce to form the biological
system of interest.
Biological network analysis offers a natural framework for anal-
ysis and interpretation of omics data sets. This said, pathway
analysis is currently more widely adopted than network analysis,
owing in part to strong methodological development and imple-
mentation, as well as straightforward biological interpretability.
The limitation of such pathway analysis is that the pathway mod-
els, by design, do not capture the intersection of these pathways
that create the entire system. While global interaction networks
inherently capture these intersections, analysis of these networks
is uniquely challenging due to their considerable size. The I2D
database6, for example, contains 173,338 human protein interac-
tions as of February 2013. A practical consideration in the analysis
of such data sets is the presence of false-positive – which are per-
vasive in online interaction databases7 – or otherwise irrelevant
interactions. Therefore, utilization of a global interaction data set
in the context of an omic analysis often requires manual cura-
tion to remove, possibly, interactions inferred by homology, or
interactions that do not physically occur in a tissue of interest.
Once such a framework network is identiﬁed, the next challenge
is to identify, which sub-regions (i.e., collections of nodes) signif-
icantly respond to a given perturbation, or correlate with a given
phenotype. A range of algorithms have been developed for this
purpose, including heuristic (Liu et al., 2007) and exact (Qiu et al.,
2009) community detection approaches, as well as network path
tracing (Morine et al., 2011).
6http://ophid.utoronto.ca
7http://nar.oxfordjournals.org/content/40/W1/W140.short
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Similar to (and possibly driven by) the to-date trend of gener-
ating and analyzing a single omic data type, molecular interaction
networks (as stored in interaction databases such as MetaCyc,
Bind, I2D, IntAct, etc.) commonly represent a single type of inter-
action – for instance, metabolic, protein-protein, or regulatory
interaction. However, it is intuitive that these classes of inter-
actions do not occur in isolation: metabolic reactions produce
metabolites, which may regulate signaling cascades, which in turn
may activate transcription regulation. Reconstruction, curation,
and analysis of such multi-level networks will be instrumental in
understanding complex, multi-factorial diseases such as T2DM
from a systems standpoint.
A notable example of this type of multi-level network is
the Biological Expression Language (BEL) framework8, which
includes a knowledge base of curated, directed interactions
and a dedicated language (i.e., a syntax and semantics). The
BEL framework contains information-rich interactions within
and between different classes of biological components. Each
8www.openbel.org
interaction is categorized by type (e.g., binding, reaction,
translocation, etc.) and includes a line of “evidence” text
parsed from the associated publication, describing the con-
text of the interaction. As an example, Figure 2 illustrates
the BEL network using a list of T2DM-related molecular pro-
cesses (based on a node keyword search for “insulin secre-
tion,” “insulin receptor signaling,” “glucose transport,” “glu-
cose import,” or “glucose homeostasis”) as seed nodes, and
then extending to the ﬁrst-degree neighbors. Apart from
demonstrating the complexity of interactions related to T2DM,
this sub-network illustrates the range of biological molecule
types that are causally associated with the diabetic pheno-
type.
Knowledge bases such as BEL demand a great deal of effort
to be curated and would therefore beneﬁt from more scien-
tiﬁc community contributions in terms of reporting identiﬁed
molecular interactions. Public transcriptomic databases have
beneﬁtted considerably by the common editorial requirement
for deposition of transcriptomic data into databases such as
Gene Expression Omnibus (GEO) and ArrayExpress. A similar
FIGURE 2 | Biological Expression Language framework network of
biological molecules that are causally linked to the T2DM molecular
phenotype. Node color indicates molecule type and/or molecular
process. Red links indicate molecular interactions, while gray links
indicate process-molecule causal relationships. The network was
constructed by extracting all nodes in the BEL knowledgebase containing
the terms “insulin secretion,” “insulin receptor signaling,” “glucose
transport,” “glucose import,” or “glucose homeostasis,” and extending to
the ﬁrst degree neighbors of these seed nodes. The result is a network
containing both molecular nodes (e.g., PRKCZ) and biological process
nodes (e.g., liver glucose import), as well as the causal relationships
between them. Some molecular nodes in the network additionally
contain a dynamic property, indicated in the node color. For instance,
cell secretion (as indicated in red) of “CHEBI: Insulin” increases
“GO: glucose transport.” Similarly, transcriptional activity (purple) of
“HGNC: PPARG” increases “GO: Insulin receptor signaling pathway.”
Abbreviations in the network nodes are as follows: CHEBI, Chemicals
of Biological Interest names (http://www.ebi.ac.uk/chebi/); EGID, Entrez
Gene IDs (http://www.ncbi.nlm.nih.gov/gene); GO, Gene Ontology names
(http://www.geneontology.org/); HGNC, Human Genome Nomenclature
Committee (http://www.genenames.org/); MESHD, Medical Subject
Heading Disease names (http://www.nlm.nih.gov/pubs/factsheets/
mesh.html); MESHCL, Medical Subject Heading Cellular Structure
(http://bioportal.bioontology.org/ontologies/46836?p=terms&conceptid=
D022082); MGI, Mouse Genome Information gene symbols (http://www.
informatics.jax.org/); NCH, Human Molecular Complex names
(http://www.ncbi.nlm.nih.gov/books/NBK7578/); PFH, Human Protein
Family names (http://mordred.bioc.cam.ac.uk/˜fpspd/Database/
nombres.html); PFM, Mouse Protein Family names (http://www.sanger.
ac.uk/resources/databases/pfam.html); RGD, Rat Genome Database gene
symbols (http://rgd.mcw.edu/); SPAC, SwissProt accession numbers
(http://www.uniprot.org/).
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requirement for deposition of interaction data in a standardized
(and information-rich) format before publication of a manuscript
could be a way of strengthening these interaction databases,
which would in turn enhance biological systems analysis and
understanding.
CONCLUSION: A SYSTEMS APPROACH TO T2DM RESEARCH
We suggest here an integrated systems approach of longitudinal
multi-omics challenge studies to reveal early molecular signs of
diabetes.We argue that this strategywill identify better biomarkers
and diagnostics that would in turn enable personalized interven-
tion through tailored diets prior to onset of chronic disease. These
interventions would consist of (micro)nutrients and other func-
tional ingredients that would be used for disease prevention rather
than disease management or cure. Having deﬁned this as one of
the key objectives in diabetes research, we acknowledge at the same
time the challenge of completely mapping out a complex human
tissue or body ﬂuid at proteomic or metabonomic level.
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